This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Trading Volatile Big Pharma Stocks

Stocks in this article: ABT AGN AZN BMY GSK JNJ LLY MRK NVO NVS PFE SNY

NEW YORK ( TheStreet) -- To invest in any big pharmaceutical company, you must investigate the reasons to own each specific stock in terms of its drug pipeline, patent issues and potential FDA decisions on the use of new drug therapies.

Stock screening tools such as www.ValuEngine.com and the analysis of chart patterns cannot anticipate how a big pharma stock will react to a specific news release. ValuEngine data is based upon financial information based upon company filings. It is purely a quantitative analysis. Price charts for any stock measures the risk/reward for the ups and downs of the stock based upon price momentum and moving averages.

My proprietary analytics distill the tug of war between the oil of equity fundamentals and the water of technical analysis. My models calculate value levels, pivots and risky levels that buy-and-trade investors can us to buy on weakness and sell on strength. In developing this discipline I have assumed that nine years of price data has anticipated all potential bullish or bearish events for any market or stock.

If you know a big pharma company and what they do in the drug world you can maintain a core long position in the stock. Then you use ValuEngine ratings, simple moving averages and my proprietary analytics to add to positions on weakness and reduce positions on strength.

Stocks continue to trade under a ValuEngine valuation warning with 70.3% of all stocks overvalued, 33.7% overvalued by 20% or more. We still show that 15 of 16 sectors are overvalued, 12 by double-digit percentages including today's featured medical sector, which is overvalued by17.1%. The large cap pharma industry is 16.4% overvalued.

Among the 12 big pharma stocks in today's table four are undervalued and eight are overvalued with six overvalued by more than 20%. Ten stocks gained by 9.7% to 43.6% over the last 12 months with only two losing ground. The projected performances over the next 12 months range from a loss of 3.8% to a gain of 8.2%. The 12 month trailing price-to-earnings ratios show two stocks with single digit P/E and two with P/E above 20.0. Three stocks are below their 200-day simple moving averages, and nine are above, which indicates the risk of reversion to the mean.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs